INVESTIGADORES
ARIAS Diego Gustavo
congresos y reuniones científicas
Título:
Drug repositioning for new treatments against Chagas disease. Oxidative damage repair enzymes from Trypanosoma cruzi as molecular targets
Autor/es:
SASONI, N; DAVIES, C; CAMPOS, EM; GARAY, AS; HERRERA, FE; RODRIGUES, D; BÜRGI, MDLM; ZAGO, MP; IGLESIAS, AA; GUERRERO, SA; ARIAS, DG
Lugar:
Salta
Reunión:
Workshop; 1st Workshop on drug discovery; 2019
Institución organizadora:
SAIB
Resumen:
Methionine is an amino acid susceptible to be oxidized to methionine sulfoxide (MetSO). The reduction of MetSO to methionine is catalyzed by methionine sulfoxide reductases (MSR), enzymes present in almost all organisms. Recently, we characterized MSR proteins from Trypanosoma cruzi, which would be relevant for the survival of these pathogens in the various stages of their life cycle. Chagas is a neglected disease caused by the parasite T. cruzi, which affects underdeveloped countries. The current drugs are nifurtimox and benznidazole, but both have severe adverse effects and less effectivity in chronic infections; therefore, the need to discover new drugs is essential. Drug repositioning is an interesting option within the international drug development community. Through molecular modeling and virtual screening using the commercially available approved drugs extracted from ZINC database (2924), we identified drugs with potential binding capacity to T. cruzi MSR. From a preliminary molecular docking analysis, a set of ten compounds with the best binding energies were selected and tested by in vitro and in vivo assays. Epimastigote and metacyclic trypomastigote cells were used to test the trypanocidal effect of ten selected compounds. Among these drugs, flunarizine, trifluoperazine, estradiol-benzoate, domperidone and itraconazole showed better or similar trypanocidal effects (IC50 range 1 to 50 mM) in comparison with nifurtimox or benznidazole (IC50 of 6 and 20 mM, respectively). In vitro enzymatic assays confirmed the inhibitory effect of these drugs over methionine sulfoxide reductase activity of T. cruzi MSRs, which exhibited similar inhibitory potency. This work suggests that five known drugs could be used to design new therapy strategies against Chagas disease. Granted by ANPCyT(PICT2014-2103, PICT2016-1778 and PICT2017-2268) and Fundación Bunge y Born (Subsidio para investigación de la enfermedadde Chagas - 2016)